Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-

[1]  L. Weiss,et al.  NTRK Fusions and Trk Proteins: What are They and How to Test for Them. , 2021, Human pathology.

[2]  Wei Zhang,et al.  A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors , 2020, Therapeutic advances in medical oncology.

[3]  S. Bielack,et al.  Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies. , 2020, European journal of cancer.

[4]  Jessica L. Davis,et al.  Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST) , 2020, Modern Pathology.

[5]  A. Gaumann,et al.  Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification , 2020, Zeitschrift für Gastroenterologie.

[6]  Y. Kodera,et al.  JSCO/ESMO/ASCO/JSMO/TOS: International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Ladanyi,et al.  Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. , 2020, The Lancet. Oncology.

[8]  A. Drilon,et al.  Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.

[9]  M. Ladanyi,et al.  Identifying patients with NTRK fusion cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  C. Zerbini,et al.  PPM11 TUMOUR-SPECIFIC RANDOMIZED CONTROLLED TRIALS IN RARE ONCOGENE-DRIVEN CANCERS: ASKING FOR THE IMPOSSIBLE? , 2019, Value in Health.

[11]  Arun K. Ramani,et al.  Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas , 2019, Nature Communications.

[12]  M. Ladanyi,et al.  NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls , 2019, Modern Pathology.

[13]  A. Zehir,et al.  Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy , 2019, The Journal of molecular diagnostics : JMD.

[14]  J. Hechtman,et al.  Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms. , 2019, Cancer research.

[15]  F. Penault-Llorca,et al.  Testing algorithm for identification of patients with TRK fusion cancer , 2019, Journal of Clinical Pathology.

[16]  Akihiko Yoshida,et al.  Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study , 2019, Cancer science.

[17]  Jessica L. Davis,et al.  TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Sicklick,et al.  Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. , 2018, JCO precision oncology.

[19]  A. Drilon,et al.  NTRK fusion-positive cancers and TRK inhibitor therapy , 2018, Nature Reviews Clinical Oncology.

[20]  A. Drilon,et al.  Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  J. Krauss,et al.  Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Jessica L. Davis,et al.  The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas , 2018, Cancer.

[23]  J. Swensen,et al.  Molecular characterization of cancers with NTRK gene fusions , 2018, Modern Pathology.

[24]  A. Drilon,et al.  Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. , 2018, Cancer discovery.

[25]  C. Fletcher,et al.  Evaluation of pan‐TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis‐like neural tumour and histological mimics , 2018, Histopathology.

[26]  Jessica L. Davis,et al.  Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors , 2018, The American journal of surgical pathology.

[27]  M. Gessler,et al.  ETV6–NTRK3 in congenital mesoblastic nephroma: A report of the SIOP/GPOH nephroblastoma study , 2018, Pediatric blood & cancer.

[28]  Funda Meric-Bernstam,et al.  Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.

[29]  Kenneth L. Jones,et al.  Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  M. Ladanyi,et al.  Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions , 2017, The American journal of surgical pathology.

[31]  A. Iafrate,et al.  Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. , 2017, JCO precision oncology.

[32]  M. Stevens,et al.  Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience. , 2016, European journal of cancer.

[33]  R. Shoemaker,et al.  Detecting Gene Rearrangements in Patient Populations Through a 2-Step Diagnostic Test Comprised of Rapid IHC Enrichment Followed by Sensitive Next-Generation Sequencing , 2016, Applied immunohistochemistry & molecular morphology : AIMM.

[34]  A. D. Dei Tos,et al.  Transcriptome sequencing identifies ETV6–NTRK3 as a gene fusion involved in GIST , 2016, The Journal of pathology.

[35]  A. Sartore-Bianchi,et al.  NTRK gene fusions as novel targets of cancer therapy across multiple tumour types , 2016, ESMO Open.

[36]  T. Vaněček,et al.  Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion , 2016, The American journal of surgical pathology.

[37]  Gang Li,et al.  Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. , 2015, Cancer discovery.

[38]  A. Vincent-Salomon,et al.  Secretory Breast Carcinoma: A Histopathologic and Genomic Spectrum Characterized by a Joint Specific ETV6-NTRK3 Gene Fusion , 2015, The American journal of surgical pathology.

[39]  Amar Gajjar,et al.  The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.

[40]  D. Deschler,et al.  Mammary analogue secretory carcinoma: Update on a new diagnosis of salivary gland malignancy , 2014, The Laryngoscope.

[41]  J. Bishop,et al.  Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma. , 2013, Human pathology.

[42]  B. Perez-Ordonez,et al.  Mammary Analogue Secretory Carcinoma of Salivary Glands, Containing the ETV6-NTRK3 Fusion Gene: A Hitherto Undescribed Salivary Gland Tumor Entity , 2010, The American journal of surgical pathology.

[43]  A. Gulino,et al.  Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma. , 2005, Future oncology.

[44]  P. Sorensen,et al.  A fluorescence in situ hybridization study of ETV6‐NTRK3 fusion gene in secretory breast carcinoma , 2004, Genes, chromosomes & cancer.

[45]  P. Sorensen,et al.  Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. , 2002, Cancer cell.

[46]  M. Caligiuri,et al.  Identification and Characterization of an Activating TrkA Deletion Mutation in Acute Myeloid Leukemia , 2022 .

[47]  P. Sorensen,et al.  Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. , 2000, The American journal of surgical pathology.

[48]  J. Fletcher,et al.  Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. , 1998, The American journal of pathology.

[49]  P. Sorensen,et al.  A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma , 1998, Nature Genetics.

[50]  A. Cantor,et al.  Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. , 1993, The New England journal of medicine.

[51]  D. Kaplan,et al.  The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. , 1991, Science.

[52]  M. Barbacid,et al.  The trk proto-oncogene encodes a receptor for nerve growth factor , 1991, Cell.

[53]  M. Barbacid,et al.  Oncogenes in solid human tumours , 1982, Nature.

[54]  R. Doebele,et al.  TRKing down an old oncogene in a new era of targeted therapy. , 2015, Cancer discovery.

[55]  H. Abel,et al.  Translocation Detection Using Next-Generation Sequencing , 2015 .

[56]  P. Argani,et al.  Detection of the ETV6-NTRK3 Chimeric RNA of Infantile Fibrosarcoma/Cellular Congenital Mesoblastic Nephroma in Paraffin-Embedded Tissue: Application to Challenging Pediatric Renal Stromal Tumors , 2000, Modern Pathology.